EVALUATION OF RISK FACTORS FOR ANTITUBERCULOSIS DRUGS-INDUCED HEPATOTOXICITY IN NEPALESE POPULATION

作者: Rajani Shakya , Bhawana Shrestha , B S Rao

DOI:

关键词:

摘要: Antitubercular drugs cause derangement of hepatic functions revealed by clinical examination and abnormal liver function test. Many factors are found to predispose patients towards this adverse reaction anti-tubercular drugs, which can economical burden as well prolong duration illness. Detection these risk for hepatotoxicity play an important role in minimizing the incidence. The present study had obejectives assess age, sex, alcohol intake, nutritional status disease extent development with active tuberculosis receiving antituberculosis treatment. 50 diagnosed infection normal pretreatment were monitored clinically biochemically a prospective cohort analysis. Four (8%) developed drug-induced hepatotoxicity. drugsinduced was prevalent younger (6% vs. 2%, P> 0.05, P = 0.368, Odds Ratio [OR]; 2.75). Female gender be at higher (P> 0.219, ratio 4.2). Majority who sputum smear positive ones advanced infection. Nutritional status, assessed body mass index (BMI) serum albumin level, next predisposing factor. Risk included female poor status. Timely detection temporary withdrawal offending agent completely cure antitubercular drugs-induced

参考文章(10)
Grangé Jd, Altman C, Biour M, Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases Presse Medicale. ,vol. 22, pp. 1212- 1216 ,(1993)
Caras Gj, Kopanoff De, Snider De, Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. The American review of respiratory disease. ,vol. 117, pp. 991- 1001 ,(1978) , 10.1164/ARRD.1978.117.6.991
J.A. Timbrell, B.K. Park, S.J. Harland, A study of the effects of rifampicin on isoniazid metabolism in human volunteer subjects. Human & Experimental Toxicology. ,vol. 4, pp. 279- 285 ,(1985) , 10.1177/096032718500400308
Jagdeep Singh, Pramod K. Garg, Rakesh K. Tandon, Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. Journal of Clinical Gastroenterology. ,vol. 22, pp. 211- 214 ,(1996) , 10.1097/00004836-199604000-00012
H. Türktaş, M. Ünsal, N. Tülek, O. Örüç, Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis Tubercle and Lung Disease. ,vol. 75, pp. 58- 60 ,(1994) , 10.1016/0962-8479(94)90104-X
Dixie E. Snider, Gus J. Caras, Isoniazid-associated hepatitis deaths: a review of available information. The American review of respiratory disease. ,vol. 145, pp. 494- 497 ,(1992) , 10.1164/AJRCCM/145.2_PT_1.494
Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su, Jaw-Ching Wu, Shinn-Liang Lai, Shi-Yi Yang, Full-Young Chang, Shou-Dong Lee, Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis Hepatology. ,vol. 35, pp. 883- 889 ,(2002) , 10.1053/JHEP.2002.32102
DONNA R. LEFF, ALAN R. LEFF, Tuberculosis control policies in major metropolitan health departments in the United States: VI. Standard of practice in 1996 American Journal of Respiratory and Critical Care Medicine. ,vol. 156, pp. 1487- 1494 ,(1997) , 10.1164/AJRCCM.156.5.9704105
JAIME R. UNGO, DENIS JONES, DAVID ASHKIN, ELENA S. HOLLENDER, DAVID BERNSTEIN, ANTHONY P. ALBANESE, ARTHUR E. PITCHENIK, Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. ,vol. 157, pp. 1871- 1876 ,(1998) , 10.1164/AJRCCM.157.6.9711039
Saroj Mehta, Malnutrition and drugs: clinical implications. Developmental pharmacology and therapeutics. ,vol. 15, pp. 159- 165 ,(1990) , 10.1159/000457640